Analysts Issue Forecasts for Opus Genetics FY2026 Earnings

Posted by George Bondi on Aug 12th, 2026

Opus Genetics, Inc. (NASDAQ:IRD – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings estimates for Opus Genetics in a research note issued on Monday, August 10th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.03) for the year, up from their prior forecast of ($1.18). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2026 earnings at ($0.09) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.27 EPS.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%.

Several other equities research analysts also recently issued reports on IRD. Citigroup started coverage on Opus Genetics in a report on Tuesday, April 28th. They issued an “outperform” rating for the company. TD Cowen initiated coverage on Opus Genetics in a research report on Wednesday, July 29th. They issued a “buy” rating for the company. Wall Street Zen upgraded Opus Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. BTIG Research reissued a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a research note on Monday, July 6th. Finally, Chardan Capital restated a “buy” rating and set a $13.00 target price on shares of Opus Genetics in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.69.

Check Out Our Latest Report on Opus Genetics

Opus Genetics Trading Up 6.0%

IRD stock opened at $3.88 on Wednesday. Opus Genetics has a 1-year low of $1.04 and a 1-year high of $5.81. The firm has a market cap of $320.68 million, a PE ratio of -2.87 and a beta of 0.59. The business’s 50-day moving average price is $3.80 and its two-hundred day moving average price is $4.14.

Insider Transactions at Opus Genetics

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of the stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the transaction, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. This represents a 0.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of Opus Genetics stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $4.35, for a total value of $7,395,000.00. Following the completion of the sale, the director directly owned 3,792,171 shares in the company, valued at $16,495,943.85. This represents a 30.95% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 1,729,331 shares of company stock valued at $7,481,629. Corporate insiders own 11.70% of the company’s stock.

Institutional Investors Weigh In On Opus Genetics

A number of hedge funds and other institutional investors have recently bought and sold shares of IRD. Occudo Quantitative Strategies LP bought a new stake in Opus Genetics in the 4th quarter valued at approximately $25,000. Comerica Bank bought a new position in shares of Opus Genetics during the 1st quarter worth approximately $29,000. Virtu Financial LLC bought a new position in shares of Opus Genetics during the 4th quarter worth approximately $34,000. Raymond James Financial Inc. raised its holdings in shares of Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new stake in shares of Opus Genetics in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.